Lymphoseek: a molecular radiopharmaceutical for sentinel node detection
Lymphoseek is a new radiopharmaceutical that accumulates in lymphatic tissue by binding to a receptor that resides on the surface of macrophage cells. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for sentinel node detection in p...
Gespeichert in:
| Veröffentlicht in: | Annals of surgical oncology 2003-06, Vol.10 (5), p.531-538 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 538 |
|---|---|
| container_issue | 5 |
| container_start_page | 531 |
| container_title | Annals of surgical oncology |
| container_volume | 10 |
| creator | Wallace, Anne M Hoh, Carl K Vera, David R Darrah, Denise D Schulteis, Gery |
| description | Lymphoseek is a new radiopharmaceutical that accumulates in lymphatic tissue by binding to a receptor that resides on the surface of macrophage cells. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for sentinel node detection in patients with breast cancer.
Twelve women (42-71 years) with breast cancer were randomly assigned to a 3-hour imaging protocol with peritumoral/subdermal injections (.5 mCi) of either Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter,.007 micro m) or.2 micro m of fTcSC. Serial images were acquired for 180 minutes. Sentinel nodes, excised within 4.2 to 7.3 hours of administration, were assayed in a dose calibrator.
The receptor-binding agent, Lymphoseek, exhibited a significantly (P =.0025) faster injection site clearance (rate,.255 +/-.147/hour; fTcSC rate,.014 +/-.018/hour); the mean Lymphoseek clearance half-time was 2.72 +/- 1.57 hours compared with 49.5 +/- 38.5 hours for fTcSC. The primary sentinel node uptake of Lymphoseek (range,.02%-1.12%; mean,.55% +/-.43%) and fTcSC (range,.00%-1.93%; mean,.65% +/-.63%) did not differ (P =.75). Lymphoseek exhibited a lower mean number of sentinel nodes per study (n = 1.3) than fTcSC (n = 1.7) and a higher concordance with Lymphazurin.
The molecular receptor-binding agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with fTcSC. |
| doi_str_mv | 10.1245/ASO.2003.07.012 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73334805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73334805</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-51d8f448df83a1c6b129c31d66f07cbce30400d89aa3ce552ab643beb5b97e853</originalsourceid><addsrcrecordid>eNpdkE1Lw0AURQdRbK2u3Ulw4S7pm69M4q4UrUKhC3U9TCYvNDXJ1Jlk0X9vSguCq_sW510uh5B7CgllQs4XH5uEAfAEVAKUXZAplVzEIs3o5XhDmsU5S-WE3ISwA6CKg7wmE8pULoDmU7JaH9r91gXE7-fIRK1r0A6N8ZE3Ze32W-NbY3Hoa2uaqHI-Ctj1dYdN1LkSoxJ7tH3tultyVZkm4N05Z-Tr9eVz-RavN6v35WIdW86gjyUts0qIrKwybqhNC8pyy2mZphUoW1jkIADKLDeGW5SSmSIVvMBCFrnCTPIZeTr17r37GTD0uq2DxaYxHbohaMU5Fxkcwcd_4M4Nvhu3acYUlypP-QjNT5D1LgSPld77ujX-oCnoo2A9CtZHwRqUHgWPHw_n2qFosfzjz0b5L7FddgY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227357963</pqid></control><display><type>article</type><title>Lymphoseek: a molecular radiopharmaceutical for sentinel node detection</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Wallace, Anne M ; Hoh, Carl K ; Vera, David R ; Darrah, Denise D ; Schulteis, Gery</creator><creatorcontrib>Wallace, Anne M ; Hoh, Carl K ; Vera, David R ; Darrah, Denise D ; Schulteis, Gery</creatorcontrib><description>Lymphoseek is a new radiopharmaceutical that accumulates in lymphatic tissue by binding to a receptor that resides on the surface of macrophage cells. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for sentinel node detection in patients with breast cancer.
Twelve women (42-71 years) with breast cancer were randomly assigned to a 3-hour imaging protocol with peritumoral/subdermal injections (.5 mCi) of either Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter,.007 micro m) or.2 micro m of fTcSC. Serial images were acquired for 180 minutes. Sentinel nodes, excised within 4.2 to 7.3 hours of administration, were assayed in a dose calibrator.
The receptor-binding agent, Lymphoseek, exhibited a significantly (P =.0025) faster injection site clearance (rate,.255 +/-.147/hour; fTcSC rate,.014 +/-.018/hour); the mean Lymphoseek clearance half-time was 2.72 +/- 1.57 hours compared with 49.5 +/- 38.5 hours for fTcSC. The primary sentinel node uptake of Lymphoseek (range,.02%-1.12%; mean,.55% +/-.43%) and fTcSC (range,.00%-1.93%; mean,.65% +/-.63%) did not differ (P =.75). Lymphoseek exhibited a lower mean number of sentinel nodes per study (n = 1.3) than fTcSC (n = 1.7) and a higher concordance with Lymphazurin.
The molecular receptor-binding agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with fTcSC.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1245/ASO.2003.07.012</identifier><identifier>PMID: 12794019</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Adult ; Aged ; Breast Neoplasms - pathology ; Dextrans ; Female ; Humans ; Injections, Subcutaneous ; Lymphatic Metastasis - diagnosis ; Macrophages ; Mannans ; Middle Aged ; Organotechnetium Compounds ; Pentetic Acid ; Radiopharmaceuticals ; Sentinel Lymph Node Biopsy - methods ; Technetium Tc 99m Pentetate - analogs & derivatives ; Technetium Tc 99m Sulfur Colloid</subject><ispartof>Annals of surgical oncology, 2003-06, Vol.10 (5), p.531-538</ispartof><rights>The Society of Surgical Oncology, Inc. 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-51d8f448df83a1c6b129c31d66f07cbce30400d89aa3ce552ab643beb5b97e853</citedby><cites>FETCH-LOGICAL-c320t-51d8f448df83a1c6b129c31d66f07cbce30400d89aa3ce552ab643beb5b97e853</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12794019$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wallace, Anne M</creatorcontrib><creatorcontrib>Hoh, Carl K</creatorcontrib><creatorcontrib>Vera, David R</creatorcontrib><creatorcontrib>Darrah, Denise D</creatorcontrib><creatorcontrib>Schulteis, Gery</creatorcontrib><title>Lymphoseek: a molecular radiopharmaceutical for sentinel node detection</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>Lymphoseek is a new radiopharmaceutical that accumulates in lymphatic tissue by binding to a receptor that resides on the surface of macrophage cells. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for sentinel node detection in patients with breast cancer.
Twelve women (42-71 years) with breast cancer were randomly assigned to a 3-hour imaging protocol with peritumoral/subdermal injections (.5 mCi) of either Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter,.007 micro m) or.2 micro m of fTcSC. Serial images were acquired for 180 minutes. Sentinel nodes, excised within 4.2 to 7.3 hours of administration, were assayed in a dose calibrator.
The receptor-binding agent, Lymphoseek, exhibited a significantly (P =.0025) faster injection site clearance (rate,.255 +/-.147/hour; fTcSC rate,.014 +/-.018/hour); the mean Lymphoseek clearance half-time was 2.72 +/- 1.57 hours compared with 49.5 +/- 38.5 hours for fTcSC. The primary sentinel node uptake of Lymphoseek (range,.02%-1.12%; mean,.55% +/-.43%) and fTcSC (range,.00%-1.93%; mean,.65% +/-.63%) did not differ (P =.75). Lymphoseek exhibited a lower mean number of sentinel nodes per study (n = 1.3) than fTcSC (n = 1.7) and a higher concordance with Lymphazurin.
The molecular receptor-binding agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with fTcSC.</description><subject>Adult</subject><subject>Aged</subject><subject>Breast Neoplasms - pathology</subject><subject>Dextrans</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Lymphatic Metastasis - diagnosis</subject><subject>Macrophages</subject><subject>Mannans</subject><subject>Middle Aged</subject><subject>Organotechnetium Compounds</subject><subject>Pentetic Acid</subject><subject>Radiopharmaceuticals</subject><subject>Sentinel Lymph Node Biopsy - methods</subject><subject>Technetium Tc 99m Pentetate - analogs & derivatives</subject><subject>Technetium Tc 99m Sulfur Colloid</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkE1Lw0AURQdRbK2u3Ulw4S7pm69M4q4UrUKhC3U9TCYvNDXJ1Jlk0X9vSguCq_sW510uh5B7CgllQs4XH5uEAfAEVAKUXZAplVzEIs3o5XhDmsU5S-WE3ISwA6CKg7wmE8pULoDmU7JaH9r91gXE7-fIRK1r0A6N8ZE3Ze32W-NbY3Hoa2uaqHI-Ctj1dYdN1LkSoxJ7tH3tultyVZkm4N05Z-Tr9eVz-RavN6v35WIdW86gjyUts0qIrKwybqhNC8pyy2mZphUoW1jkIADKLDeGW5SSmSIVvMBCFrnCTPIZeTr17r37GTD0uq2DxaYxHbohaMU5Fxkcwcd_4M4Nvhu3acYUlypP-QjNT5D1LgSPld77ujX-oCnoo2A9CtZHwRqUHgWPHw_n2qFosfzjz0b5L7FddgY</recordid><startdate>20030601</startdate><enddate>20030601</enddate><creator>Wallace, Anne M</creator><creator>Hoh, Carl K</creator><creator>Vera, David R</creator><creator>Darrah, Denise D</creator><creator>Schulteis, Gery</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20030601</creationdate><title>Lymphoseek: a molecular radiopharmaceutical for sentinel node detection</title><author>Wallace, Anne M ; Hoh, Carl K ; Vera, David R ; Darrah, Denise D ; Schulteis, Gery</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-51d8f448df83a1c6b129c31d66f07cbce30400d89aa3ce552ab643beb5b97e853</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Breast Neoplasms - pathology</topic><topic>Dextrans</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Lymphatic Metastasis - diagnosis</topic><topic>Macrophages</topic><topic>Mannans</topic><topic>Middle Aged</topic><topic>Organotechnetium Compounds</topic><topic>Pentetic Acid</topic><topic>Radiopharmaceuticals</topic><topic>Sentinel Lymph Node Biopsy - methods</topic><topic>Technetium Tc 99m Pentetate - analogs & derivatives</topic><topic>Technetium Tc 99m Sulfur Colloid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wallace, Anne M</creatorcontrib><creatorcontrib>Hoh, Carl K</creatorcontrib><creatorcontrib>Vera, David R</creatorcontrib><creatorcontrib>Darrah, Denise D</creatorcontrib><creatorcontrib>Schulteis, Gery</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wallace, Anne M</au><au>Hoh, Carl K</au><au>Vera, David R</au><au>Darrah, Denise D</au><au>Schulteis, Gery</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lymphoseek: a molecular radiopharmaceutical for sentinel node detection</atitle><jtitle>Annals of surgical oncology</jtitle><addtitle>Ann Surg Oncol</addtitle><date>2003-06-01</date><risdate>2003</risdate><volume>10</volume><issue>5</issue><spage>531</spage><epage>538</epage><pages>531-538</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>Lymphoseek is a new radiopharmaceutical that accumulates in lymphatic tissue by binding to a receptor that resides on the surface of macrophage cells. We conducted a phase I clinical trial in which Lymphoseek was compared with filtered [(99m)Tc]sulfur colloid (fTcSC) for sentinel node detection in patients with breast cancer.
Twelve women (42-71 years) with breast cancer were randomly assigned to a 3-hour imaging protocol with peritumoral/subdermal injections (.5 mCi) of either Lymphoseek (1 nmol; molecular weight, 28 kDa; diameter,.007 micro m) or.2 micro m of fTcSC. Serial images were acquired for 180 minutes. Sentinel nodes, excised within 4.2 to 7.3 hours of administration, were assayed in a dose calibrator.
The receptor-binding agent, Lymphoseek, exhibited a significantly (P =.0025) faster injection site clearance (rate,.255 +/-.147/hour; fTcSC rate,.014 +/-.018/hour); the mean Lymphoseek clearance half-time was 2.72 +/- 1.57 hours compared with 49.5 +/- 38.5 hours for fTcSC. The primary sentinel node uptake of Lymphoseek (range,.02%-1.12%; mean,.55% +/-.43%) and fTcSC (range,.00%-1.93%; mean,.65% +/-.63%) did not differ (P =.75). Lymphoseek exhibited a lower mean number of sentinel nodes per study (n = 1.3) than fTcSC (n = 1.7) and a higher concordance with Lymphazurin.
The molecular receptor-binding agent Lymphoseek demonstrated faster injection site clearance and equivalent primary sentinel node uptake when compared with fTcSC.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>12794019</pmid><doi>10.1245/ASO.2003.07.012</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1068-9265 |
| ispartof | Annals of surgical oncology, 2003-06, Vol.10 (5), p.531-538 |
| issn | 1068-9265 1534-4681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73334805 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Breast Neoplasms - pathology Dextrans Female Humans Injections, Subcutaneous Lymphatic Metastasis - diagnosis Macrophages Mannans Middle Aged Organotechnetium Compounds Pentetic Acid Radiopharmaceuticals Sentinel Lymph Node Biopsy - methods Technetium Tc 99m Pentetate - analogs & derivatives Technetium Tc 99m Sulfur Colloid |
| title | Lymphoseek: a molecular radiopharmaceutical for sentinel node detection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T23%3A41%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lymphoseek:%20a%20molecular%20radiopharmaceutical%20for%20sentinel%20node%20detection&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Wallace,%20Anne%20M&rft.date=2003-06-01&rft.volume=10&rft.issue=5&rft.spage=531&rft.epage=538&rft.pages=531-538&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1245/ASO.2003.07.012&rft_dat=%3Cproquest_cross%3E73334805%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227357963&rft_id=info:pmid/12794019&rfr_iscdi=true |